Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | PPOX | P50336 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10272188 | 1.00 | BCL2L1 (0.34) | BCL2L1ADORA3PTPN11CASP1KMT2A | |
| SCHEMBL10272108 | 0.81 | CA2 (0.30) | CA2 | |
| SCHEMBL10272174 | 0.81 | CA2 (0.30) | CA2 | |
| SCHEMBL1699422 | 0.81 | CA2 (0.30) | CA2 | |
| SCHEMBL1699653 | 0.80 | ALOX15 (0.41) | ADORA3CASP1KMT2AMEN1 | |
| SCHEMBL15093506 | 0.76 | SMN1; SMN2 (0.39) | BCL2L1ADORA3KMT2AMEN1CYP2C9 | |
| SCHEMBL1699748 | 0.75 | ADORA3 (0.47) | ADORA3KMT2AMEN1 | |
| SCHEMBL15093746 | 0.74 | ALDH1A1 (0.41) | ADORA3 | |
| SCHEMBL15093489 | 0.74 | ALDH1A1 (0.39) | ADORA3 | |
| SCHEMBL16657255 | 0.74 | ALDH1A1 (0.39) | ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588450-B1 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES INC (US) | 2017-05-24 | — | — | EP | disclosed |
| EP-2588450-B1 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES INC (US) | 2017-05-24 | — | — | EP | disclosed |
| US-9102614-B2 | Naphth-2-ylacetic acid derivatives to treat AIDS | GILEAD SCIENCES, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-9102614-B2 | Naphth-2-ylacetic acid derivatives to treat AIDS | GILEAD SCIENCES, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-9102614-B2 | Naphth-2-ylacetic acid derivatives to treat AIDS | GILEAD SCIENCES, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20130203727-A1 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203727-A1 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203727-A1 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| EP-2588450-A1 | NAPHT- 2 -YLACETIC ACID DERIVATIVES TO TREAT AIDS | Gilead Sciences, Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| WO-2012003497-A1 | NAPHT- 2 -YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012003497-A1 | NAPHT- 2 -YLACETIC ACID DERIVATIVES TO TREAT AIDS | GILEAD SCIENCES, INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203727-A1 | NAPHT-2-YLACETIC ACID DERIVATIVES TO TREAT AIDS | NFATC1, AADAT, ACAT1 | BCL2L1 3967/4885ADORA3 415/4885PTPN11 2711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.